

Victor J. Dzau, M.D. (*Chair, International Oversight Group*) is the President of the National Academy of Medicine (NAM), formerly the Institute of Medicine (IOM). In addition, he serves as Chair of the IOM Division Committee of the National Academies of Sciences, Engineering, and Medicine. He is Chancellor Emeritus and James B. Duke Professor of Medicine at Duke University and the past President and CEO of the Duke University Health System. Previously, Dr. Dzau was the Hersey Professor of Theory and Practice of Medicine and Chairman of Medicine at Harvard Medical School's Brigham and Women's Hospital, as well as Chairman of the Department of Medicine at Stanford University.

Dr. Dzau has made a significant impact on medicine through his seminal research in cardiovascular medicine and genetics, his pioneering of the discipline of vascular medicine, and his leadership in health care innovation. His important work on the renin angiotensin system (RAS) paved the way for the contemporary understanding of RAS in cardiovascular disease and the development of RAS inhibitors as widely used, lifesaving drugs. Dr. Dzau also pioneered gene therapy for vascular disease, and his recent work on stem cell paracrine mechanisms and the use of microRNA in direct reprogramming provides novel insight into stem cell biology and regenerative medicine.

In his role as a leader in health care, Dr. Dzau has led efforts in health care innovation. His vision is for academic health sciences centers to lead the transformation of medicine through innovation, translation, and globalization. Leading this vision at Duke, he and his colleagues developed the Duke Translational Medicine Institute, the Duke Global Health Institute, the Duke-National University of Singapore Graduate Medical School, and the Duke Institute for Health Innovation. These initiatives create a seamless continuum from discovery and translational sciences to clinical care, and they promote transformative innovation in health.

As one of the world's preeminent academic health leaders, Dr. Dzau advises governments, corporations, and universities worldwide. He has been a member of the Council of the IOM and the Advisory Committee to the Director of the National Institutes of Health (NIH), as well as Chair of the NIH Cardiovascular Disease Advisory Committee and the Association of Academic Health Centers. He served on the Governing Board of the Duke-National University of Singapore Graduate Medical School and the Board of Health Governors of the World Economic Forum and chaired its Global Agenda Council on Personalized and Precision Medicine. He also served as the Senior Health Policy Advisor to Her Highness Sheikha Moza (Chair of the Qatar Foundation). Currently, he is a member of the Board of Directors of the Singapore Health System, the Expert Board of the Imperial College Health Partners, UK, and the International Advisory Board of the Biomedical Science Council of Singapore. In 2011, he led a partnership between Duke University, the World Economic Forum, and McKinsey, and he founded the International Partnership for Innovative Healthcare Delivery and currently chairs its Board of Directors.

Among his honors and recognitions are the Gustav Nylin Medal from the Swedish Royal College of Medicine; the Max Delbrück Medal from Humboldt University, Charité, and the Max Planck Institute; the Commemorative Gold Medal from the Ludwig Maximilian University of Munich; the Inaugural Hatter Award from the Medical Research Council of South Africa; the Polzer Prize from the European Academy of Sciences and Arts; the Novartis Award for Hypertension Research; the Distinguished Scientist Award from the American Heart Association (AHA); and the AHA Research Achievement Award for his contributions to cardiovascular biology and medicine. Recently, he was awarded the Public Service Medal by the President of Singapore. He has received eight honorary doctorates.

Irene Akua Agyepong, Dr.P.H., MBChB, M.P.H., FGCPs, is a public health physician from Ghana employed by the Ghana Health Service. She has also taught and supervised students' part time in the University of Ghana School of Public Health since its inception in 2004. In 2012, the Ghana Health Service seconded her full-time to the Department of Health Policy, Planning,

and Management of the University of Ghana's School of Public Health. Prior to this she was Regional Director of Health Services in the Ghana Health Service Greater Accra region from 2004 to 2012, and before that District Director of Health for the Dangme West district. She was Professor to the Prince Claus Chair in Development and Equity from 2008 to 2010 at the University of Utrecht in the Netherlands, based in the Julius Center of the University Medical Center. She was chair of the 11-member Board of Health Systems Global, an international membership society for the promotion and development of the field of health policy and systems research globally from 2012 to 2014. She has been a member (since 2006) and Chair (2009–2013) of the Scientific and Technical Advisory Committee of the Alliance for Health Policy and Systems Research.

Dr. Agyepong has an MBChB from the University of Ghana Medical School, a Master's of Public Health from the Liverpool School of Tropical Medicine, Part I of the West Africa College of Physicians and Surgeons in Public Health, and a Doctorate in Public Health from the University of North Carolina at Chapel Hill School of Public Health. She is a Foundation Fellow of the Ghana College of Physicians and Surgeons.

Maria Freire, Ph.D., is the President of Foundation for the National Institutes of Health. She comes to the Foundation from the Albert and Mary Lasker Foundation, where she served as President since 2008. Prior to joining the Lasker Foundation, Dr. Freire served as President and CEO of the Global Alliance for TB Drug Development from 2001 to 2008, Director of the Office of Technology Transfer at the National Institutes of Health from 1995 to 2001, and led the Office of Technology Development at the University of Maryland at Baltimore and the University of Maryland Baltimore County from 1989 to 1995. Dr. Freire received her Bachelor of Science degree at the Universidad Peruana Cayetano Heredia in Lima, Peru and her Ph.D. in Biophysics from the University of Virginia. She has also completed post-graduate work in immunology and virology at the University of Virginia and the University of Tennessee, respectively. Dr. Freire has devoted her career to improving health and health research on a global scale.

Margaret Hamburg, M.D., is Foreign Secretary for the National Academy of Medicine. Previously, she was the 21st Commissioner of Food and Drugs, only the second woman to serve in the position. Among her initiatives during her tenure at FDA, Dr. Hamburg oversaw the modernization of a food safety system to reduce foodborne illness; advancement of biomedical innovation through the approval of novel medical products in cutting-edge areas of science and medicine; the securing of a safer globalized food and medical product supply chain; and implementation of the Family Smoking Prevention and Tobacco Control Act to reduce the death and disease caused by tobacco.

At the center of her work was a focus on strengthening the agency's ability to apply the best available science to the challenges before it, to allow the agency to respond to new technologies and to the opportunities afforded by the growing understanding of the underlying mechanisms of disease.

In the area of nutrition, FDA oversaw changes in several areas to promote more informed and healthier choices, such as helping reduce trans fat in processed foods, clarifying "gluten free" labeling, updating the Nutrition Facts on the food label, and finalizing rules to provide caloric information on chain restaurant menus and vending machines. Enhancement of the safety, effectiveness, and availability of medical products was achieved through a number of initiatives and actions, including new congressional authority for oversight of drug compounding, establishment of a regulatory pathway for biosimilar biological products, a substantial reduction in the time taken for pre-market review of new medical devices, and the rapid approval of crucial medicines for rare types of cancer, hepatitis C, type-2 diabetes, idiopathic pulmonary fibrosis, and other diseases.

As part of its new authority provided by Congress to regulate tobacco products, FDA entered into agreements with numerous state and local authorities to enforce the ban on the sale of tobacco products to children and teens; proposed an important rule to expand the types of products covered by the law; and launched a public education campaign to prevent and reduce tobacco use among our nation's youth.

Dr. Hamburg received her M.D. from Harvard Medical School in 1983 and completed her residency in internal medicine at what is now New York–Presbyterian Hospital/Weill Cornell Medical Center. She conducted research on neuroscience at Rockefeller University, studied neuropharmacology at the National Institute of Mental Health, and later focused on AIDS research as assistant director of the National Institute of Allergy and Infectious Diseases. From 1991 to 1997, Dr. Hamburg served as commissioner of the New York City Department of Health and Mental Hygiene. In this position she focused on improved services for women and children, promoted needle-exchange programs to reduce the spread of HIV, initiated the nation's first public health bioterrorism defense program, and in particular, worked on curbing the spread of tuberculosis, a serious and resurgent public health threat in the 1990s. The latter initiative included sending health care workers to patients' homes to make sure they completed the drug regimen, which became a model for health departments worldwide and led to a significant reduction in New York City's TB rate over a five-year span.

Her distinctive service as an experienced medical doctor, scientist, and public health executive led to her election to membership in the prestigious National Academy of Medicine in 1994, one of the youngest persons to achieve that honor. In 1997, Dr. Hamburg accepted the position of assistant secretary for policy and evaluation in the U.S. Department of Health and Human Services.

From 2005 to 2009, Dr. Hamburg was the senior scientist at the Nuclear Threat Initiative, a foundation dedicated to reducing the threat to public safety from nuclear, chemical, and biological weapons. From 2001 to 2005, as the foundation's vice president for biological programs, she advocated for broad reforms to confront the dangers of modern bioterrorism as well as the threats of naturally occurring infectious diseases such as pandemic flu.

Gabriel Leung, M.D., M.P.H., became the fortieth Dean of the Li Ka Shing Faculty of Medicine at the University of Hong Kong in 2013. Leung, a clinician and a respected public health authority, concurrently holds the Chair of Public Health Medicine. Previously he was Professor and Head of Community Medicine at the University and served as Hong Kong's first Under Secretary for Food and Health and fifth Director of the Chief Executive's Office in government.

Dr. Leung is one of Asia's leading epidemiologists, having authored more than 400 scholarly papers and edited numerous journals. His research defined the epidemiology of two novel viral epidemics, namely SARS coronavirus in 2003 and influenza A (H7N9) in 2013. While in government, he led Hong Kong's policy response against the 2009 influenza A (H1N1) pandemic. Leung currently directs the University's WHO Collaborating Centre for Infectious Disease Epidemiology and Control. He was inaugural Chair of the Asia Pacific Observatory on Health Systems and Policies during 2010–2014. He regularly advises national and international agencies including the World Health Organization, World Bank, Asian Development Bank and the Chinese Center for Disease Control and Prevention.

Judith Rodin, Ph.D. (*Vice Chair, International Oversight Group*) Judith Rodin is president of The Rockefeller Foundation, one of the world's leading philanthropic organizations. She was previously president of the University of Pennsylvania, and provost of Yale University. Since joining the Foundation in 2005, Dr. Rodin has recalibrated its focus to meet the challenges of the 21st century and today the Foundation supports and shapes innovations to expand opportunity worldwide and build greater resilience by helping people, communities and institutions prepare for, withstand and emerge stronger from acute shocks and chronic stresses.

The Foundation accomplishes these goals through work that advances health, revalues ecosystems, secures livelihoods, and transforms cities.

A widely recognized international leader in academia, science, and development issues, Dr. Rodin has actively participated in influential global forums, including the World Economic Forum, the Council on Foreign Relations, Clinton Global Initiative, and the United Nations General Assembly. Dr. Rodin is also a member of the African Development Bank's High Level Panel and a Board member of the Alliance for a Green Revolution in Africa (co-created by The Rockefeller Foundation). In November 2012, New York Governor Andrew Cuomo named Dr. Rodin to co-chair the NYS 2100 Commission on long-term resilience following Superstorm Sandy.

A pioneer and innovator throughout her career, Dr. Rodin was the first woman named to lead an Ivy League Institution and is the first woman to serve as The Rockefeller Foundation's president. A research psychologist by training, she was one of the pioneers of the behavioral medicine and health psychology movements.

Dr. Rodin is the author of more than 250 academic articles and has written or co-written 15 books, including her two most recent, [The Power of Impact Investing](#) and [The Resilience Dividend: Being Strong in a World Where Things Go Wrong](#). She has received 19 honorary doctorate degrees and has been named one of Crain's 50 Most Powerful Women in New York. She has also been recognized as one of Forbes Magazine's World's 100 Most Powerful Women three years in a row.

Dr. Rodin serves as a member of the board for several leading corporations and nonprofits, including Citigroup, Laureate Education, Inc., Comcast, and the White House Council for Community Solutions. She is a graduate of the University of Pennsylvania and earned her Ph.D. in psychology from Columbia University.

Peter Sands, M.P.A. (*Chair, GHRF Commission*) is a senior fellow at the Mossavar-Rahmani Center for Business and Government at Harvard Kennedy School. He is also lead non-executive director of the Board of the United Kingdom's Department of Health. Mr. Sands was Group Chief Executive of Standard Chartered Bank from November 2006 to June 2015. He joined the Board of Standard Chartered PLC as Group Finance Director in May 2002. Before his appointment as Group Chief Executive he was responsible for Finance, Strategy, Risk and Technology and Operations. Prior to joining Standard Chartered, Mr. Sands was a director with worldwide consultants McKinsey & Company. He had been with McKinsey since 1988 where he worked extensively in the banking and technology sectors in a wide range of international markets. He was elected a partner in 1996 and became a director in 2000. Prior to joining McKinsey, he worked for the United Kingdom's Foreign and Commonwealth Office. Mr. Sands graduated from Oxford University and holds a Master's in Public Administration from Harvard University, where he was a Harkness Fellow.

Lawrence H. Summers, Ph.D., is the Charles W. Eliot University Professor and President Emeritus of Harvard University. During the past two decades, he has served in a series of senior policy positions in Washington, D.C., including the 71st Secretary of the Treasury for President Clinton, Director of the National Economic Council for President Obama and Vice President of Development Economics and Chief Economist of the World Bank. He received a bachelor of science degree from the Massachusetts Institute of Technology in 1975 and was awarded a Ph.D. from Harvard in 1982. In 1983, he became one of the youngest individuals in recent history to be named as a tenured member of the Harvard University faculty. In 1987, Mr. Summers became the first social scientist ever to receive the annual Alan T. Waterman Award of the National Science Foundation (NSF), and in 1993 he was awarded the John Bates Clark Medal, given every two years to the outstanding American economist under the age of 40.

He is currently the Charles W. Eliot University Professor at Harvard University and the Weil Director of the Mossavar-Rahmani Center for Business & Government at Harvard's Kennedy School. He and his wife Elisa New, a professor of English at Harvard, reside in Brookline with their six children.